Keyword Analysis & Research: glanatec
Keyword Research: People who searched glanatec also searched
Search Results related to glanatec on Search Engine
-
Ripasudil - Wikipedia
https://en.wikipedia.org/wiki/Ripasudil
webRipasudil (trade name Glanatec), a derivative of fasudil, is a rho kinase inhibitor drug (previously known as K-115) used for the treatment of glaucoma and ocular hypertension.
DA: 51 PA: 81 MOZ Rank: 63
-
Glanatec | Prescription Drugs | Our Products | Kowa …
https://kowa-pharma.asia/products/glanatec/
webGlanatec. Scan the QR code linked to package insert. At the time of the development of Glanatec® ophthalmic solution 0.4%, glaucoma treatment drugs were prostaglandin (PG) -related drugs, β-blockers, αβ-blockers, α1 blockers, carbonic anhydrase inhibitors, sympathomimetics, and α2 agonist.
DA: 91 PA: 89 MOZ Rank: 18
-
Ripasudil: Uses, Interactions, Mechanism of Action | DrugBank …
https://go.drugbank.com/drugs/DB13165
webJan 20, 2017 · This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered. Type. Small Molecule. Groups. Experimental. Structure. Similar Structures. Weight. Average: 323.39.
DA: 46 PA: 65 MOZ Rank: 53
-
Ripasudil hydrochloride hydrate - D.Western Therapeutics Institute…
https://dwti.co.jp/english/product-pipeline/glanatec/
webTOP. Pipeline. Ripasudil hydrochloride hydrate. ①Glaucoma and ocular hypertension [GLANATEC® ophthalmic solution 0.4%] This drug is an eye drop preparation with a novel mechanism of action, the first of its kind in the world, for treating glaucoma.
DA: 84 PA: 1 MOZ Rank: 63
-
Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212985/
webMay 6, 2020 · Ripasudil hydrochloride hydrate (brand name: Glanatec ophthalmic solution 0.4%; Kowa Company, Ltd., Japan; hereafter referred to as ripasudil) is the world’s first Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor eyedrop that lowers IOP by increasing conventional aqueous outflow through the trabecular meshwork and ...
DA: 39 PA: 58 MOZ Rank: 34
-
Safety, efficacy, and patient selection of ripasudil in patients with
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359231/
webMay 31, 2022 · Ripasudil was approved by the Pharmaceuticals and Medical Device Agency (PMDA) of Japan on September 26, 2014, under the brand name Glanatec (ophthalmic solution 0.4%) as the world’s first glaucoma drug with a Rho kinase inhibitory activity, and it was approved in 2019 in Korea.
DA: 3 PA: 70 MOZ Rank: 81
-
Ripasudil: first global approval - PubMed
https://pubmed.ncbi.nlm.nih.gov/25414122/
webAbstract. Ripasudil hydrochloride hydrate (Glanatec® ophthalmic solution 0.4 %; hereafter referred to as ripasudil) is a small-molecule, Rho-associated kinase inhibitor developed by Kowa Company, Ltd. for the treatment of glaucoma and ocular hypertension.
DA: 67 PA: 8 MOZ Rank: 27
-
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188806/
webThe glaucomas are a group of progressive optic neuropathies characterized by optic disc excavation and apoptotic loss of retinal ganglion cells with corresponding vision loss 1 .
DA: 54 PA: 60 MOZ Rank: 12
-
Ripasudil: First Global Approval | Drugs - Springer
https://link.springer.com/article/10.1007/s40265-014-0333-2
webNov 21, 2014 · Ripasudil hydrochloride hydrate (Glanatec®; hereafter referred to as ripasudil) is a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, an “outflow” drug which reduces IOP by stimulating aqueous humour drainage through the trabecular meshwork [ 3 ].
DA: 8 PA: 15 MOZ Rank: 73
-
Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for …
https://www.liebertpub.com/doi/10.1089/jop.2019.0125
webMay 6, 2020 · Ripasudil (ie, Glanatec ® Ophthalmic Solution 0.4%; Kowa Co., Ltd., Nagoya, Japan) was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension. 8 ROCK inhibitor eye drops, a new class of antiglaucoma medications, have been shown to lower IOP by modulating the cytoskeleton and focal adhesions in …
DA: 93 PA: 24 MOZ Rank: 15